Cassava Sciences Announces New Website Launch
![]() AUSTIN, Texas, May 28, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com. Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. “Our re-designed website was developed to serve and to communicate with our stakeholders,” said Remi Barbier, President & CEO. “It’s also intended to convey our commitment and strong excitement for the development and use of biomarkers and new drugs for Alzheimer’s disease.” Cassava Sciences recently completed a Phase 2a safety study in Alzheimer’s disease with PTI-125, a new drug with a novel mechanism of action. Funding for this Phase 2 study was provided by the National Institutes of Health (NIH). Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed. About Cassava Sciences, Inc. About Our Research Programs We are also developing a diagnostic to detect Alzheimer’s disease with a simple blood test. In blinded studies our investigational diagnostic, PTI-125Dx, detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects. The underlying science for our research programs is published in prestigious peer-reviewed technical journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation. In 2018, NIH awarded us two research grants following an in-depth, confidential review of our science and technology. These NIH grants represent up to $6.7 million of non-dilutive financing. Please visit our website for more information: www.CassavaSciences.com About Alzheimer's Disease For More Information Contact: Eric Schoen Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cassava Sciences disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the timing of clinical studies and the potential benefits of the Company’s programs in Alzheimer’s disease, including our ongoing Phase II program. The Company cautions that forward-looking statements are inherently uncertain. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the ability to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates and including those described in the section entitled “Risk Factors” in Cassava’s Annual Report on Form 10-K for the year ended December 31, 2018. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. ![]() |
|